34
Participants
Start Date
March 10, 2016
Primary Completion Date
December 1, 2018
Study Completion Date
April 11, 2019
Avelumab
Anti-PD-L1 antibody at X1 mg IV every 2 weeks to optimize dosing for expansion. Treatment with avelumab will continue until disease progression.
Avelumab
Anti-PD-L1 antibody at X2 mg IV every 2 weeks to optimize dosing for expansion. Treatment with avelumab will continue until disease progression.
Avelumab
Anti-PD-L1 antibody at X3 mg IV every 3 weeks to optimize dosing for expansion. Treatment with avelumab will continue until disease progression
Avelumab
Anti-PD-L1 antibody at X3 mg IV every 2 weeks to optimize dosing for expansion. Treatment with avelumab will continue until disease progression
Avelumab
Anti-PD-L1 antibody at X mg IV every 2 weeks. Treatment with avelumab will continue until disease progression
Avelumab
Anti-PD-L1 antibody at X1 mg IV every 2 weeks which can be escalated to X4 mg every 2 weeks based on safety and efficacy. Treatment with avelumab will continue until disease progression.
Istituto Clinico Humanitas U.O. Oncologia ed Ematologia, Rozzano
Az. Ospedaliera-Univers. di Bologna Policlinico S.Orsola-Malpighi, Bologna
City of Hope, Duarte
Q2 Solutions, Rosebank
Oxford University Hospitals NHS Foundation Trust, Headington
Leeds Teaching Hospital NHS Trust, Leeds
St James's University Hospital, Leeds
University Hospitals of Leicester NHS Trust, Leicester
University Hospitals of Leicester NHS Trust, Leicester
University College London Hospitals NHS Foundation Trust, London
UCLH Clinical Research Facility, London
The Christie NHS Foundation Trust, Manchester
Plymouth Hospitals NHS Trust, Derriford Hospital, Plymouth
Lead Sponsor
Pfizer
INDUSTRY